General information
MorphoSys AG
Semmelweisstr. 7
82152 Planegg, Bavaria
Germany
Contact person: Julia Neugebauer, Senior Director Investor Relations
Company main phone: +49 (89) 899270
Company main fax: +49 (89) 89927222
Website: www.morphosys.com
Year founded: | 1992
|
Source of foundation: | Independent foundation |
No. of employees: |
Worldwide: 648 |
Corporate description / mission:
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases, with a focus on cancer. The company's product include Tafasitamab (MOR208, formerly Xmab®5574) an investigational monoclonal antibody directed against the antigen CD19 which is broadly expressed on the surface of B cells.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 1999
Categorization
Sector: |
- Biotechnology - Therapeutics and Diagnostics
|
Subsector: |
- Anti-infectives
- Antibodies
- Immunotherapy
- Peptides
|
Primary therapeutic areas: |
- Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
- Diseases of the nervous system / neurology
- Endocrine, nutritional and metabolic diseases / endocrinology
- Musculoskeletal system and connective tissue / Orthopedics
- Neoplasms / cancer / oncology
- Skin and subcutaneous tissue / dermatology
- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
|
Business model: |
- Manufacturer
- R&D
- Supplier / Distributor
|
Customer segments: |
- Hospitals
- Large biotech & big pharma
- Small biotech
|
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical: | 1 | |
Phase I: | 26 | |
Phase II: | 34 | |
Phase III: | 16 | |
On the market: | 2 | |
Description of products:
Tafasitamab
Pelabresib
CPI-0209, etc.
Special IP situation:
MorphoSys has built a strong IP portfolio around its proprietary technology, HuCAL.
Technology used:
HuCAL (Human Combinatorial Antibody Library) technology
Financing details
Fiscal year (end of) 2021
Revenues: | EUR 179.61M | |
R&D expenses: | EUR 225.21M | |
No. of shares: | 34'153'400 | |
Market cap. / valuation: | EUR 767.82M | |
Collaborations & Clients
Partnering strategy / collaborations:
Novartis
I-Mab
GSK
pfizer
Ultragenyx and Mereo Biopharma etc